Searching for Biomarkers to Better Guide Melanoma Therapy Searching for Biomarkers to Better Guide Melanoma Therapy

Dr Jeffrey Weber explores the phase 3 COMBI-AD melanoma trial. Could tumor mutational burden alone or in combination with interferon gamma gene signature be a prognostic factor?Medscape Oncology
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news